therapiAI, a leading AI pharmaceutical company, announced today the launch of the world’s first AI Agent dedicated to Antibody-Drug Conjugates (ADCs). This technology significantly compresses the traditional 2-3 year R&D exploration phase. By following the AI Agent’s recommendations, researchers can